Comments
Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET
Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma
BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?
Read
Commented by Juliane Zielonka on November 15th, 2024 | 07:00 CET
First Hydrogen, BYD, Porsche - Two newcomers challenge the old guard
Germany is establishing itself as a pioneer in hydrogen mobility with an ambitious 9,700 km hydrogen network and 17 specialized hydrogen centers. The Company First Hydrogen is taking advantage of this momentum and is positioning itself in the German market with its field-tested commercial vehicles at exactly the right time. With an impressive range of 630 km per tank fill and successful fleet trials in the UK, First Hydrogen is making strides. At the same time, Hungary is developing into a strategic hub of European e-mobility. With BYD and BMW setting up operations and the battery manufacturer CATL investing EUR 7.3 billion, a major center for electromobility is emerging here. Once the undisputed star in the automotive sky, Porsche is experiencing a decline in revenue of 5.2% to EUR 28.56 billion and is struggling with a falling operating return. The important Chinese market, particularly, is causing concern for the Stuttgart-based company, where sales figures fell by a third in the first half of the year.
Read
Commented by Juliane Zielonka on November 14th, 2024 | 07:45 CET
Daimler Truck, dynaCERT, Bayer AG: Contrasts in Q3: Established companies under pressure, newcomers with breakthroughs
Established DAX corporations such as Bayer AG and Daimler Truck, a Mercedes-Benz Group company, are facing a headwind in the third quarter of 2024. However, the Canadian cleantech specialist dynaCERT is on the verge of its commercial breakthrough. The Leverkusen-based Bayer Group has to revise its forecast downwards. The agriculture business, in particular, is a cause for concern, while the pharmaceuticals division is scoring points with new drugs. At Daimler Truck, strong business in North America is stabilizing the balance sheet, while business in Europe is under pressure. dynaCERT, on the other hand, has received the valuable Verra certification for its hydrogen technology for diesel optimization after twenty years of development work. Investors finally have a viable hydrogen use case for logistics.
Read
Commented by Fabian Lorenz on November 14th, 2024 | 07:30 CET
Big news for Siemens Energy and F3 Uranium! Shock at Plug Power!
A golden age for uranium. The US aims to triple its nuclear energy capacity, and uranium explorers such as F3 Uranium should benefit massively from this. Like the uranium price, stocks in the sector have consolidated and are currently offering an exciting entry opportunity. This year, Siemens Energy has impressively demonstrated how quickly things can go up. Now, the DAX-listed company has also raised its medium-term targets. However, the wind power division continues to struggle. At Plug Power, revenue is now also faltering. Shareholders of the hydrogen specialist have become accustomed to losses, but they are still higher than revenue. Can it go on like this?
Read
Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET
The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus
The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.
Read
Commented by Fabian Lorenz on November 14th, 2024 | 07:00 CET
SHARE PRICES EXPLODE as biotech stocks rise! BioNTech, Evotec, Nyxoah
Is Evotec about to make a quick turnaround? A financial investor is positioning itself for a potential takeover, and the stock surged significantly in the last days. Does this mean that the disappointment over the quarterly figures has been forgotten? Could Nyxoah's stock be the next to skyrocket? The chances of this are good. The medtech company expects FDA approval for the first quarter of 2025 and aims to roll out its main product across the US market next year. Analysts see billion-dollar potential, rapidly increasing revenues, and a favourable P/E ratio. BioNTech shares are also benefiting from a rating upgrade by renowned analysts. The target price has been raised significantly. Could this help the German biotech leader break out of its recent consolidation phase?
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read
Commented by Fabian Lorenz on November 13th, 2024 | 07:00 CET
Over 100% PRICE GAIN? Nel ASA, SAP, and Myriad Uranium share in analyst review
The new Trump administration is likely to give nuclear energy - and consequently uranium - a further boost. At the same time, Internet giants such as Google and Amazon have already chosen nuclear energy as the solution to their energy needs. Myriad Uranium has a project in the US, and analysts see a 175% upside potential. Experts are also convinced by SAP. They see the software company as the top pick in Europe. However, the stock has already seen significant gains. Nel, on the other hand, has completely different problems. The hydrogen market, despite political support, is simply not gaining momentum. Analysts even consider a new multi-year low possible and recommend selling. Is an acquisition the only answer?
Read
Commented by André Will-Laudien on November 12th, 2024 | 08:00 CET
Traffic light disaster brings new opportunities for e-mobility: VW, BMW, ARI Motors, BYD and NIO
The traffic light coalition has broken down – so right before left applies! In addition to the Berlin disaster, a relentless struggle has long since broken out in the automotive market. Habeck, for example, wants to get the environmental subsidy back in 2025 due to a sharp drop in electric vehicle sales, while important market shares of German industry have long since been lost. Germany is making only hesitant progress in the area of energy transition, while nuclear energy is experiencing a renaissance worldwide. Fortunately, innovative concepts are repeatedly emerging from medium-sized companies, driving Germany forward as a business location. With a new, forward-looking industrial policy, Germany could regain its leading position. For dynamic investors, this is an explosive environment with extraordinary opportunities for high returns.
Read
Commented by Stefan Feulner on November 12th, 2024 | 07:45 CET
Rheinmetall, 123fahrschule, Freenet – On the verge of a further upward surge
The traffic light is red, and the coalition government formed by the SPD, FDP and the Greens has failed. What remains behind is an ever-weaker economy. Irrespective of this, the German leading index, DAX, is moving towards its all-time high of 19,670 points after a brief dip last week due to the US election. German small-cap companies have also caused a stir in recent days and offer promising entry opportunities at the current level.
Read